Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

doi:10.1093/infdis/164.4.646

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

The Journal of infectious diseases - 1 Oct 1991

Johnson V A, Merrill D P, Videler J A, Chou T C, Byington R E, Eron J J, D'Aquila R T, Hirsch M S

Abstract excerpt

Optimal management of human immunodeficiency virus type 1 (HIV-1) infections may require combinations of anti-HIV-1 agents. Zidovudine (AZT, 3'-azido-3'-deoxythymidine), didanosine (ddI, 2',3'-dideoxyinosine), and recombinant interferon-alpha A (rIFN-alpha A) were evaluated in two-drug regimens against replication of AZT-resistant HIV-1 in vitro. AZT-sensitive and AZT-resistant isolate pairs derived from two...

Topics

Base Sequence
Cells, Cultured
Codon
DNA, Viral
Didanosine
Drug Resistance, Microbial
Drug Synergism
Genotype
HIV-1
Humans
Interferon Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Leukocytes, Mononuclear

Molecular Sequence Data

Mutation

RNA-Directed DNA Polymerase

Recombinant Proteins

Virus Replication

Zidovudine

Source

Open in PubMed

Identifiers

PMID: 1716649
DOI: 10.1093/infdis/164.4.646

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-1716649-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.PMID 1716649Read ↗

Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.Semantic proximity Read ↗

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.Semantic proximity Read ↗

Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination TherapySemantic proximity Read ↗

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.Semantic proximity Read ↗

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.Semantic proximity Read ↗

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.Semantic proximity Read ↗

Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.Semantic proximity Read ↗

Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or DDI but no by combinations.Semantic proximity Read ↗

A Mathematical Model of Combined Drug Therapy of HIV InfectionSemantic proximity Read ↗

3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.Semantic proximity Read ↗

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.Semantic proximity Read ↗

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.